March 21, 2013
Bloomberg recently reported that pharmaceutical company Novo Nordisk (NYSE: NVO ) , in collaboration with a small biotech company called Merrion Pharmaceuticals, recently completed a phase 1 study for an oral insulin drug. The experimental medication, known only as NN1954, could help the company's revenue grow over the long term if it eventually gains approval. However, Motley Fool health care analyst Max Macaluso believes that investors shouldn't get too excited about this news just yet. Watch the following video to find out why and how Novo Nordisk's project may one day become a threat to Sanofi's (NYSE: SNY ) mega-blockbuster insulin drug Lantus.
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year -- unfortunately, neither Novo Nordisk nor Sanofi made the cut. Find out which stock it is in the brand-new free report: "The Motley Fool's Top Stock for 2013." Just click here to access the report and find out the name of this under-the-radar company.